Post by Myriad Genetics

𝐈𝐬 𝐌𝐑𝐃 𝐛𝐞𝐜𝐨𝐦𝐢𝐧𝐠 𝐜𝐞𝐧𝐭𝐫𝐚𝐥 𝐭𝐨 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭? As precision oncology advances, researchers and developers now detect treatment response 𝐞𝐚𝐫𝐥𝐢𝐞𝐫, 𝐝𝐞𝐞𝐩𝐞𝐫, 𝐚𝐧𝐝 𝐦𝐨𝐫𝐞 𝐚𝐜𝐜𝐮𝐫𝐚𝐭𝐞𝐥𝐲, reshaping how teams develop and evaluate therapies. In a new episode of Fierce Pharma's The Top Line, Dale Muzzey, Chief Scientific Officer, and Louis Welebob, Senior Vice President of Biopharma and Companion Diagnostics, explore how 𝐭𝐮𝐦𝐨𝐫-𝐢𝐧𝐟𝐨𝐫𝐦𝐞𝐝 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐫𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 (𝐌𝐑𝐃) 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 is emerging as a powerful tool in clinical trials and companion diagnostics, helping biopharma teams: 🔵 Detect response earlier in the treatment journey 🔵 Improve patient selection and trial design 🔵 Generate deeper, quantitative insights into tumor dynamics over time 🔵 Make more informed decisions to potentially accelerate development When teams integrate diagnostics earlier in development, they mitigate risk, improve efficiency, and ultimately drive better outcomes for patients. 🎧Listen to the full discussion to learn how MRD is shaping the future of #oncology drug development and companion diagnostics. 👉 https://lnkd.in/eTwrfySU #MRD #precisionmedicine #biopharma #ctDNA #drugdevelopment #companiondiagnostics #clinicaltrials